Our mission is to reimagine medicine to improve and extend people’s lives, developing and delivering transformative medicines for patients in Europe and around the world. Novartis is a leader in Europe in innovative, generic and biosimilar medicines. Novartis appreciates the Commission (EC)’s recognition of the urgent need to modernize the regulatory framework.
NIA
Novartis International AG
Company · Belgium · EU Transparency Register 91269481588-28
8
positions filed
in the 665 files tracked
8
legislative files
of 665 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #193 by legislative files engaged, a count of participation, not a measure of influence.
3.2
declared lobbying FTE
self-declared
€2.5M+
declared costs / yr (floor)
6
EP accreditations
as declared to the register
2009
in the register since
Declares membership of
- Business Europe Membership
- Critical Medicines Alliance
- ECPA
- EFPIA - Pillar 3 IMI
- EFPIA (Pillar 1+2)
- EFPIA: Pillar 3 ICH
- EFPIA Country engagement
- EFPIA Campaign mode
- EFPIA - Contribution to Fairer pharmaceutical spending & improved industrial ecosystem in Europe 'advocacy 1 communic…
- Eucope (Membership)
- Eucope Membership - Support to the incentive Steering Group (ISG)
- Eucope Membership (OLU WG)
- and 19 more
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Head office
- Basel, Switzerland
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Novartis in PolicySpeak: request access →
Work at Novartis International AG? so we know who speaks for it.
Their record over time
Novartis International AG filed 8 positions between 5 Jan 2021 and 5 Aug 2026, across 8 of the 665 legislative files tracked here, attaching a full position paper 2 times.
2021 · 3 filed2022 · 2 filed2026 · 3 filed
What they argued
Novartis welcomes the European Commission's first-of-its-kind legislative proposal on the use of Artificial intelligence (AI), which positions the EU as leader in trustworthy AI and digital. As healthcare company, we use this innovative science to discover and develop medicines. AI technologies are transforming how we innovate and operate and they offer high potential for improving healthcare quality.
Novartis welcomes the Biotech Act as a concrete step towards strengthening Europes life sciences ecosystem. By promoting simplification, regulatory coherence, reduced administrative burden and a stronger IP framework, the Act can support innovation and enhance Europes attractiveness for research, development, manufacturing and investment. To maximise its impact, Novartis highlights three priorities. 1.
Novartis commends the Commission for suggesting regulation around a European Health Data Space (EHDS), which could be a game changer for the digital transformation of healthcare in the EU. The regulation has many benefits for patients, who will have the right to control and share their personal electronic health data.
Novartis welcomes the European Commissions initiative to strengthen early detection and screening of cardiovascular diseases (CVDs) as a core pillar of the EU Safe Hearts Plan. CVDs remain the leading cause of mortality and morbidity in Europe, requiring more systematic and appropriate CV risk stratification to reduce avoidable disease, health inequalities and long-term pressure on health systems.
At Novartis, our mission is to reimagine medicine to improve and extend people’s lives, including transformative medicines for rare disease patients and children in Europe and around the world. Novartis appreciates the Commission (EC)’s recognition of the importance of orphan medicinal products (OMPs) and paediatric medicines in its IIA and we welcome the objectives of stimulating more development in areas of unmet…
Bringing new therapies to patients is a long, complex and risky process that requires long-term and continuous investments. Patents are critical to that purpose and to the EU’s innovation and industrial ambitions.
Lifesaving nuclear medicine should be regulated with the same rigor as other nuclear activities, but not in the same way. For innovative radiopharmaceuticals, high safety standards can be maintained while reducing unnecessary system burden by applying a pragmatic, risk and exposure-based approach to radioactive waste management, grounded in low medical doses, low volumes, safe handling conditions, and real-world…
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Novartis International AG next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 169.
Is this your organization?
Everything on this page comes from Novartis International AG’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.